Answer:T cells, tumor-infiltrating lymphocytes, peripheral blood lymphocytes and other compatible immune-cell populations.
Answer:Yes. It contains phenol red, gentamicin and L-glutamine.
Answer:Lonza has scheduled the formulation for discontinuation at the end of 2026 and identifies an alternative X-VIVO 15 medium for transition.
Lonza X-VIVO 15 is a serum-free hematopoietic cell culture medium supplied in a 1 L bottle for research involving lymphocytes and other immune cells. The formulation contains L-glutamine, gentamicin and phenol red and supports work with purified CD3-positive T cells, tumor-infiltrating lymphocytes, peripheral blood lymphocytes, natural killer cells, monocytes and macrophages. The balanced medium enables cell expansion without the addition of serum in suitable research protocols. This research-use formulation is separate from GMP-grade TheraPEAK media and is not intended for clinical administration or GMP manufacturing. The manufacturer has scheduled this specific formulation for discontinuation at the end of 2026; laboratories planning repeat orders can evaluate the designated replacement X-VIVO 15 formulation.
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
